Business Wire

Xsolla Expands Into India With Paytm Payment Gateway to Help Developers Sell Games to the India Market

Share

Xsolla, the video game business engine that helps developers and publishers launch and operate games globally, today announced it teamed up with Paytm Payment Gateway, India's leading payments solutions provider, to bring gaming payments solutions to India.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126006130/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Xsolla expands into India with Paytm payment gateway (Graphic: Business Wire)

Xsolla integrated Paytm’s Digital Wallet, Unified Payment Interface (UPI), and online banking payment solutions into its Pay Station platform. Video game developers and publishers can monetize their products in India giving them access to the massive gaming marketplace of more than 400 million gamers, second only to China’s playerbase.

“India has become one of the fastest-growing game economies in Asia, bringing in approximately $1.5B annually, with growth expected to nearly triple by 2024,” said Xsolla’s Head of Payments and Commerce, Anton Zelenin. “Historically, India’s payments market has been dominated by cash, and is only now evolving to meet the demands of its increasingly smartphone-led online shopping culture. To sell successfully in this country, developers need access to multiple payment methods which can be complicated. This is where Xsolla brings value with our payment solutions to interface with pre-integrated local payment methods.”

“We are happy to partner with a global brand like Xsolla,” said Praveen Sharma, Sr. Vice President - Paytm. “The gaming industry in India has been on the upward growth trajectory over the past few years, and this is a trend that will continue in the coming times. The solutions that Xsolla is providing to the industry are path-breaking and we’re proud to be their payments partner in this journey.”

Any merchant seeking to sell in India requires a local entity and local bank account. The integration with Paytm Payment Gateway establishes Xsolla as the merchant of record for its clients, enabling them to bypass the time-consuming process. Xsolla is one of a select few services to offer India local payments for cross-border clients.

To learn more about Xsolla Pay Station offerings visit: https://xsolla.pro/xps

To learn more about the gaming economy in India, download our ebook at: https://xsolla.pro/ieb

About Xsolla

Xsolla is the world's leading video game commerce company, with a robust and powerful set of tools and services designed specifically for the games industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes to promote and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla continues to solve the inherent complexities of global distribution, marketing, and monetization so their partners can grow audience, engagement, and revenue. With offices worldwide, Xsolla currently works with major gaming entities like Valve, Twitch, Roblox, Ubisoft, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more. For additional information, please visit xsolla.com.

Xsolla - Accelerate Your Video Game Commerce - https://xsolla.pro/agc

About Paytm

Paytm is India's leading financial services company that offers full-stack payments & financial solutions to consumers, offline merchants and online platforms. The company is on a mission to bring half a billion Indians into the mainstream economy through payments, commerce, banking, investments, and financial services. One97 Communications Limited that owns the brand Paytm is founded by Vijay Shekhar Sharma and is headquartered in Noida, Uttar Pradesh. Its investors include Softbank, Ant Financial, AGH Holdings, SAIF Partners, Berkshire Hathaway, T Rowe Price, and Discovery Capital.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Viktoria Rogozhnikova
v.rogozhnikova@xsolla.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination

Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib

New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release

Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet

Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release

On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan

Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release

Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of